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Ras homolog enriched in brain (Rheb) is critical
for mechanistic target of rapamycin complex 1
(mTORC1) activation in response to growth factors
and amino acids (AAs). Whereas growth factors
inhibit the tuberous sclerosis complex (TSC1-
TSC2), a negative Rheb regulator, the role of AAs in
Rheb activation remains unknown. Here, we identify
microspherule protein 1 (MCRS1) as the essential
link between Rheb and mTORC1 activation.
MCRS1, in an AA-dependent manner, maintains
Rheb at lysosome surfaces, connecting Rheb to
mTORC1.MCRS1 suppression in human cancer cells
using small interference RNA or mouse embryonic
fibroblasts using an inducible-Cre/Lox system re-
duces mTORC1 activity. MCRS1 depletion promotes
Rheb/TSC2 interaction, rendering Rheb inactive and
delocalizing it from lysosomes to recycling endocytic
vesicles, leading to mTORC1 inactivation. These
findings have important implications for signaling
mechanisms in various pathologies, including dia-
betes mellitus and cancer.
INTRODUCTION
Growth factor and nutrient signals are integrated through mech-
anistic/mammalian target of rapamycin (mTOR), a serine/threo-
nine phosphoinositide-related kinase often deregulated in
cancer (Laplante and Sabatini, 2012). mTOR complex 1
(mTORC1) integrates growth factors through phosphoinosi-
tide-3 kinase (PI3K)/protein kinase B (PKB), which inactivates
the tuberous sclerosis complex (TSC1-TSC2) tumor suppressor,
a negative mTORC1 regulator. The TSC1-TSC2 complex has
guanosine triphosphatase (GTPase)-activating protein (GAP) ac-
tivity for Ras homolog enriched in brain (Rheb), a Ras-like gua-
nosine triphosphate (GTP)-binding protein required for mTORC1
activation (Garami et al., 2003; Inoki et al., 2003; Saucedo et al.,
2003; Stocker et al., 2003; Zhang et al., 2003b). Thus, Rheb is
inactivated in guanosine diphosphate (GDP)-bound form, but
the GTP-bound form directly stimulates mTORC1 (Avruch
et al., 2009). Hence, loss of TSC1 or TSC2 renders Rheb hyper-
active, activating mTORC1, which becomes resistant to growth
factor, but not AA deprivation, (Kim et al., 2008; Roccio et al.,
2006; Sancak et al., 2008; Smith et al., 2005; Zhang et al.,2003b). Accordingly, AA deprivation reduces active GTP-bound
Rheb levels (Roccio et al., 2006; Smith et al., 2005), implying
that mechanisms controlling mTORC1 by AAs are TSC2-
independent.
AAs reportedly activate mTORC1 through the lysosome-asso-
ciated machinery for AA sensing involving Rag GTP-binding pro-
teins (Sancak et al., 2008), the scaffolding complex Ragulator
(Bar-Peled et al., 2012; Sancak et al., 2010; Zoncu et al.,
2011a), and vacuolar H+-adenosine triphosphatase (v-ATPase)
(Zoncu et al., 2011b). The first essential step in AA-induced
mTORC1 activation is its recruitment to lysosomes by Rag
proteins, providing an activation platform on which mTORC1 co-
localizes with GTP-bound Rheb (Sancak et al., 2008). Rheb is
therefore necessary but insufficient for mTORC1 activation.
We identify microspherule protein 1 (MCRS1) as a molecular
link connecting Rheb-GTP to mTORC1 activation at lysosomes
in AA responses. MCRS1 depletion promotes Rheb/TSC2 inter-
action and delocalizes Rheb from lysosomes to recycling endo-
cytic vesicles, resulting in mTORC1 inactivation.RESULTS
MCRS1 Binds Rheb-GTP in an AA-Dependent Manner
To elucidate Rheb regulation in AA responses, we sought Rheb
interactors with mass spectrometry to identify GST-Rheb-asso-
ciated proteins in human embryonic kidney (HEK)-293T cells
overexpressing GST (glutathione-S-transferase) or GST-Rheb.
Identified proteins with high peptide scores included mTORC1
components (mTOR, Raptor, mLST8), TSC2, and MCRS1 (Fig-
ure 1A). MCRS1 is overexpressed in colorectal cancer (Shi
et al., 2009, 2012), so the potential Rheb-MCRS1 interaction
was validated in pull-down assays using human colorectal carci-
noma HCT-116 and HEK293T cells. Immunoblotting of GST
precipitated by specific antibodies identified MCRS1 (Figures
1B and S1A). Similarly, MCRS1 was detected in pull-down as-
says when purified bacterially expressed recombinant wild-
type GST-Rheb was incubated with HEK293T or HCT-116 whole
cell lysates (Figure S1B). The specificity of MCRS1 binding to
Rheb in vitro was verified using lysates of HCT-116 cells trans-
fected with non-silencing control small interference RNA
(siRNA-Ctr) or various MCRS1-depleting siRNAs (siRNA-
MCRS1) (Figures S1C and S1D). We also mapped the Rheb-
binding part ofMCRS1, using bacterially expressed recombinant
GST-Rheb and in vitro translated MCRS1 (Figures 1C, 1D, and
S1E), a highly conserved C-terminal (Ct) segment. Moreover, us-
ing in vitro translated HA-Rheb fragments, we identified Rheb
N-terminal (Nt) as the MCRS1-binding part (Figure 1E).Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc. 67
Figure 1. MCRS1 Binds Rheb-GTP in an AA-Dependent Manner
(A) HEK293T cells transiently expressingGST or GST-Rhebwere lysed, subjected to GST pull-down assays, and protein complexeswere resolved on SDS-PAGE
followed by coomassie staining. GST, GST-Rheb and the interacting protein MCRS1 are indicated on the figure.
(B) GST pull-downs from HEK293T and HCT-116 cells transiently expressing GST or GST-Rheb.
(C) GST pull-downs from bacteria purified GST and GST-Rheb incubated with in vitro translated fragments of HA-MCRS1.
(D) In vitro translated HA-MCRS1 fragments used in Figure 1C.
(E) In vitro translated fragments of HA-Rheb were incubated with HCT-116 cell lysate and immunoprecipitated using an HA antibody.
(F) HCT-116 cells transiently expressing either GST, GST-Rheb (wt), GST-Rheb switch 1mutant (I39K), GST-Rheb switch 2mutant (D60I), and GST-Rhebmutant
unable to undergo prenylation (C181S) were lysed and subjected to GST pull-down assays.
(G) GST pull-downs from HCT-116 cells transiently transfected with either Rheb (wt), the constitutively active form of Rheb (Q64L) or with a nucleotide-deficient
Rheb mutant (S20N). Immunoblots of short exposure (s.e) and long exposure (l.e) are shown.
(H) Quantification of (G).
(I) HCT-116 cells were serum-starved for 16 hr followed by 1 hr AA deprivation (lanes 1, 2, 5, 6, and 9) or 1 hr AA deprivation and then AA stimulation for 10 min
(lanes 3, 4, 7, 8, and 10). Lysates were subjected to immunoprecipitation assays.
(J) HCT-116 cells transfected either with siRNA control (Ctr) or against MCRS1 or Rheb were lysed and subjected to immunoprecipitation assays.
Statistical analyses were performed using one-way ANOVA test followed by the Bonferroni method (H). Errors bars represent ± SD (n = 3). **p% 0.01.Next, we tested the MCRS1-binding ability of three GST-Rheb
mutants overexpressed in HCT-116 cells. MCRS1 binding to
Rheb (C181S), a mutant unable to undergo the prenylation/far-
nesylation required for Rheb-membrane interaction and activity,
was significantly reduced. Whereas interaction of MCRS1 to
Rheb (I39K), carrying a mutation in the Rheb switch 1 region
that exhibited similar Rheb-wt GTP binding, was slightly
affected, MCRS1 binding was drastically diminished for Rheb
(D60I), carrying a mutation in the Rheb switch 2 region interfering68 Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc.selectively with GTP binding in vitro (Long et al., 2005a) (Fig-
ure 1F). We therefore tested whether MCRS1 affinity to Rheb de-
pends on Rheb’s nucleotide-binding state. The dominant active
mutant Rheb-Q64L (90% GTP charged) showed higher affinity
for MCRS1 than both the inactive, strongly nucleotide-deficient
mutant Rheb-S20N (Long et al., 2005a, 2005b) and Rheb-wt
(Figures 1G and 1H). However, Rheb-wt bound substantial
amounts of MCRS1 because of its potent GTP-binding (Inoki
et al., 2003) (Figures 1G and 1H). Loading bacterially expressed
Figure 2. MCRS1 Interacts with mTOR
(A) Size exclusion chromatography of cytoplasmic fraction from HCT-116 cells. The collected fractions were processed for immunoblotting.
(B) HCT-116 cells transfected either with siRNA-Ctr, siRNA-MCRS1, or siRNA-mTOR were lysed and subjected to immunoprecipitation assays.
(C) HCT-116 cells transfected with either siRNA-Ctr or siRNA-MCRS1were serum-starved for 16 hr followed by 1 hr AA deprivation (lanes 1, 2, 5, and 6) or 1 hr AA
deprivation and then AA stimulation for 10 min (lanes 3, 4, 7, and 8). Lysates were subjected to immunoprecipation assays.
(D) HEK293T cells transiently expressing HA-tagged full-length MCRS1 (1–462), N terminal (1–260), or C terminal (256–462) were lysed and subjected to
immunoprecipitation using an HA antibody.
(E) HCT-116 cells transfected with either empty plasmid (pRK5) or different Myc-tagged mTOR fragments were lysed and immunoprecipitated using Myc
antibody.recombinant GST-Rheb-wt with GTP also enhanced MCRS1/
Rheb interaction (Figure S1F). Importantly, reciprocal co-immu-
noprecipitation experiments indicated that AAs strongly
enhanced endogenous MCRS1/Rheb association (Figures 1I
and 1J). In vitro Rheb’sGST pull-downs or Rheb endogenous im-
munoprecipitates in different cell lines confirmed that AA deple-
tion reversibly reduced MCRS1 interaction with Rheb (Figures
S1G–S1K). Glucose deprivation in the absence of AAs was not
sufficient to promote MCRS1/Rheb interaction (Figures S1I
and S1J), suggesting that AAs are essential in MCRS1/Rheb
interaction. Inhibiting the v-ATPase and Ragulator by knocking
down ATP6V0C and LAMTOR1, respectively, had no effect on
Rheb/MCRS1 interaction (Figure S1H). However, both leucine
and non-essential AAs promotedMCRS1/Rheb association (Fig-
ures S1I and S1J), suggesting that MCRS1/Rheb interaction isinfluenced by AA-sensing pathways independent of the
v-ATPase and Ragulator axis. Furthermore, MCRS1/Rheb asso-
ciation was not further enhanced in the presence of insulin-like
growth factor (IGF)-1, although IGF1 alone slightly increased
MCRS1/Rheb interaction (Figures S1I and S1J). Interestingly,
endogenous Rheb interacted in a similar fashion with full-length
and Ct MCRS1 in response to AAs (Figure S1K). Finally, AA or
MCRS1 depletion impaired Rheb/mTOR interaction (Figures
S1I and S1L) in multiple cell lines. Thus, MCRS1 binds active
Rheb in an AA-dependent manner.
MCRS1 Interacts with mTOR
MCRS1 co-eluted in the same fractions as mTORC1 in gel filtra-
tion assays (Figure 2A). The ability of MCRS1 to form complexes
with mTORC1 was checked with co-immunoprecipitation withDevelopmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc. 69
three custom-made MCRS1 antibodies (Figure S2A). Further-
more, reciprocal co-immunoprecipitation assays detected
endogenous MCRS1 in a complex with mTOR/Raptor in HCT-
116, human colon adenocarcinoma SW-620 (Figures 2B and
S2B) and HEK293T (Figure S2C) cells. Notably, Sin1 (an
mTORC2 member) did not co-immunoprecitate with MCRS1,
suggesting that MCRS1 forms a complex with mTORC1 but
not mTORC2 (Figure 2B). Additionally, AAs did not dramatically
enhance endogenous mTOR/MCRS1 association (Figures 2C
and S2D). Interestingly, MCRS1 bindsmTOR and Rheb indepen-
dently, as shown by co-immunoprecipitation of endogenous
MCRS1 in Rheb-depleted HCT-116 cells and byGST pull-downs
in mTOR-depleted HCT-116 cells (Figures S2E and S2F).
In vitro binding assays indicated that Nt (1–260) part but not Ct
(256–462) segment of MCRS1 specifically boundmTOR (Figures
2D, S2G, and S2H) Notably, URI, a regulator of mTOR/S6K1
axis (Djouder et al., 2007) did not bind to mTOR (Figure S2H).
Finally, overexpressing Myc-mTOR fragments in HCT-116 cells
and Myc immunoprecipitation assays showed that mTOR
boundMCRS1 through its Nt part (Figure 2E). Thus, MCRS1 pro-
vides a molecular platform connecting Rheb to mTORC1 in AA
responses.
MCRS1 Is Essential for mTORC1 Activation
MCRS1 knockdown impaired mTORC1 activation in HCT-116
cells under normal growth conditions, manifested by dephos-
phorylations of two mTORC1 targets: S6K1 at Thr-389 and
4EBP1 at Ser-65 (Figure 3A). Similarly, MCRS1 depletion in
HEK293T cells using siRNAs targeting various regions of
MCRS1 mRNA (Figure S3A) abolished mTORC1 activation,
also in response to AAs and/or IGF1 in HCT-116 (Figure 3B),
HeLa (Figure S3B), and SW-620 (not shown) cells. To exclude
the possibility that MCRS1 acts on the energy sensor AMP-acti-
vated kinase (AMPK), which inhibits mTORC1 signaling under
glucose deprivation (Jewell and Guan, 2013), we depleted
MCRS1 and analyzed AMPK activation through Thr-172 phos-
phorylation. MCRS1 suppression dephosphorylated S6K1
without affecting AMPK activity, indicating that MCRS1 regu-
lates mTORC1 independently of energy depletion (Figure S3C).
Notably, AAs depletion, independently of MCRS1 suppression,
slightly increased AMPK activity but, as with MCRS1 knock-
down, did not significantly modify cellular ATP levels (Dennis
et al., 2001) (Figure S3D). Interestingly, MCRS1 localizes to
minus ends of chromosomal microtubules and K-fibers, pro-
tecting them from depolymerization (Meunier and Vernos,
2011). However, MCRS1 knockdown in HCT-116 cells did not
depolymerize microtubules (Figure S3E). Moreover, MCRS1
depletion in HCT-116 cells treated with the microtubule-depoly-
merizing compound nocodazole did not affect (or slightly
increased) phosphorylation of 4EBP1 and S6K1 at Thr-389 (Fig-
ure S3F). Thus MCRS1 depletion-mediated mTORC1 inactiva-
tion is independent of microtubule network changes. Finally,
depleting cells of NDE1, a centrosomal MCRS1-interacting pro-
tein implicated in cell division and survival (Hirohashi et al.,
2006), did not affect S6K1 phosphorylation, excluding the po-
tential nuclear function of MCRS1 in mTORC1 activation
(Figure S3G).
In further tests, we generated conditional MCRS1 knockout
mice by introducing the MCRS1 floxed allele by homologous70 Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc.recombination in embryonic stem cells (Figures S3H–S3K).
Immortalized mouse embryonic fibroblasts (MEFs) from mice
carrying theMcrs1 lox allele infected with adenoviruses express-
ing Cre recombinase (adeno-Cre) for at least 48 hr to delete
MCRS1 (MCRS1/) resulted in severe mTORC1 activity inhibi-
tion, as shown by S6K1 dephosphorylation at Thr-389 (Fig-
ure 3C). We also isolated MEFs fromMCRS1lox/lox mice crossed
with Tg-UQ-CreERT2 mice, a transgenic line expressing tamox-
ifen-inducible Cre recombinase under ubiquitin C promoter con-
trol (Ruzankina et al., 2007). Both MCRS1 levels and mTORC1
activation were reduced in tamoxifen-treatedMEFs (Figure S3L).
Importantly, PKB phosphorylation at Ser-473 slightly increased
in MCRS1’s absence (Figure S3M), indicating that MCRS1 regu-
lates mTORC1 independently of mTORC2.
Next, we examined MCRS1 depletion effects in TSC2/
MEFs, which display constitutively active Rheb and chronic
mTORC1 activation. TSC2/ MEFs were stably infected with
lentiviral-based particles for integrating and expressing isopro-
pyl b-D-1-thiogalactopyranoside (IPTG)-inducible small hairpin
RNA (shRNA) targeting a non-coding sequence (shRNA-Ctr) or
two silencing Mcrs1 mRNA (sh1RNA-MCRS1 and sh2RNA-
MCRS1). Mcrs1 deletion in the presence of IPTG reduced
mTORC1 activity, as revealed by S6K1 phosphorylation at
Thr-389 (Figures 3D and S3N), confirming the existence of
TSC2-independent but MCRS1-specific mechanisms control-
ling mTORC1 activation in AA responses.
Additionally, MCRS1 depletion decreased cell number and
size of HCT-116, HeLa (Figures 3E–3H), and HEK293T cells
(Figure S3O). These effects were mostly pronounced in HeLa
cells, which showed higher levels of MCRS1 and higher S6K1
activation than HCT-116 or HEK293T cells (Figure S3P). More-
over, MCRS1 knockdown reduced survival of HCT-116 (Figures
3I–3K) and HeLa (Figures S3Q–S3S) cells and decreased cell
number in various MCRS1/ MEFs (Figure S3T). Activated
autophagy measured by accumulation of lipidated LC3 was
also detected in TSC2/, HEK293T, and HCT-116 cells (Fig-
ures 3L–3N and S3U). Finally, overexpression of MCRS1 frag-
ments Ct (256-462, Rheb-binding) and Nt (1-260, non-Rheb-
binding) respectively enhanced and impaired mTORC1 activity,
in HeLa, HEK293T, and HCT-116 cells (Figure S3V). These ef-
fects correlated with Rheb/mTOR association (Figure S3W)
and cell number in HeLa and HEK293T cells (Figure S3X), sug-
gesting that MCRS1 Nt (1–260), which does not bind to Rheb
(Figure 1C), acts as a dominant-negative fragment. Thus,
MCRS1 regulates cellular functions that may be associated
with mTORC1.
MCRS1 Expression Is Enhanced in Human Colorectal
Cancer and Correlates with mTORC1 Activation
Finally, enhanced MCRS1 expression in human colorectal can-
cers, detected with immunohistochemistry using a MCRS1 anti-
body, correlated with poor patient prognosis and tumor stage,
increased proliferation, and mTORC1 activation (revealed by
S6K1 and S6 phosphorylation at Thr-389 and Ser-240/244,
respectively) (Figures 4 and S4). These results concur with re-
ported deregulation of MCRS1 expression (Shi et al., 2009,
2012) and mTORC1 activation (Gulhati et al., 2009) in colon can-
cer, and suggest that MCRS1 is oncogenic through mTORC1
activation.
Figure 3. MCRS1 Is Essential for mTORC1 Activation
(A) HCT-116 cells cultured under normal growth conditions were transfected with siRNA-Ctr (control) or siRNA-MCRS1.
(B) HCT-116 cells transfected with either siRNA-Ctr (lanes 1–5) or siRNA-MCRS1 (lanes 6–10) were cultured under normal conditions (lanes 1 and 6) or serum-
starved for 16 hr followed by AA deprivation for 1 hr (lanes 1, 2, 4, 6, 7, and 9) or AA deprivation and then re-stimulated by AAs (lanes 3 and 8) or IGF1 (lanes 4 and 9)
for 10 min or both (lanes 5 and 10).
(C) MCRS1+/+ or MCRS1lox/lox MEFs were infected or not infected with adeno-Cre lentiviral particles for 48 hr.
(D) TSC2/MEFs stably expressing either shRNA-Ctr (control) (lanes 1 and 2) or sh1RNA against MCRS1 (Sh1RNA-MCRS1) (lanes 3 and 4) were cultured in the
absence (lanes 1 and 3) or presence (lanes 2 and 4) of IPTG for 36 hr.
(E–H) Cell number (E andG) and cell diameter (F and H) was assessed in HCT-116 (E and F) andHeLa (G andH) cells transfected either with siRNA-Ctr (red square)
or siRNA-MCRS1 (blue diamond) or treated with 20 nM of rapamycin (purple circle).
(I) Colony formation assay was performed in HCT-116 cells transfected either with siRNA-Ctr or siRNA-MCRS1.
(J and K) Quantification of colony number (J) and size (K) from (I) using ImageJ.
(L and M) Immunofluorescence images of TSC2/ MEFs, MCRS1 depleted (sh1RNA-MCRS1) (L) and HEK293T cells either treated with siRNA-Ctr or siRNA-
MCRS1 (M) and transiently transfected with GFP-LC3.
(N) HEK293T (lanes 1 and 2) and HCT-116 (lanes 3 to 6) cultured in normal growth conditions in presence of FCS were transfected with either siRNA–Ctr (control)
(lane 1) or three different siRNA targeting MCRS1 mRNA.
Statistical analysis was performed using two-way ANOVA test followed by the Benferroni method (E–H) and t test (J and K). Errors bars represent ± SD (n = 3).
*p% 0.05, **p% 0.01, and ***p% 0.001. Scale bars represent 5 mm.MCRS1 Regulates Rheb Activity
Hypothesizing that MCRS1 activates mTORC1 through Rheb,
we checked whether MCRS1 regulates farnesylation, required
for Rheb activity. Fractionations of HCT-116 and HEK293T cells
revealed that Rheb was cytoplasmic following AA or MCRS1
depletion, but relocalized to the nucleus when HCT-116 cells
were treated with the farnesyltransferase inhibitor FTI-277 (Fig-
ures S5A–S5D), a known effect of farnesylation inhibition (Bassoet al., 2006; Buerger et al., 2006; Jiang and Vogt, 2008; Takaha-
shi et al., 2005). Thus, neither AA nor MCRS1 depletion affects
Rheb farnesylation.
Because MCRS1 binds to active Rheb (Rheb-GTP) in an
AA-dependent manner, we asked whether MCRS1 affects its
nucleotide-binding state. Use of an immunoprecipitation Rheb-
GTP-specific antibody (Figures S5E and S5F) showed that AA
or MCRS1 depletion in HCT-116 cells significantly reducedDevelopmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc. 71
Figure 4. MCRS1 Expression Is Enhanced in Human Colorectal Cancer and Correlates with mTORC1 Activation
(A–F) Immunohistochemistry of MCRS1 expression in paired non tumoral (A, C, and E) and tumoral (B, D, and F) samples from three different patients.
(G) Kaplan Meier curve for high and low MCRS1 expression in human colon tumors. p = 0.05 and Cox regression = 0.035
(H–K) Correlation of MCRS1 expression in human colon tumors with tumor stage (H), Ki-67 (proliferation marker) (I), and mTORC1 activation revealed by pThr-
389/412-S6K1 (pS6K1) (J) and pSer-240/244-S6 (pS6) (K).
Differences in number of cases among immunohistochemical markers were due to tissue damage (either tissue loss or inadequate tumor tissue). Scale bars
represent 100 mm.Rheb-GTP levels and impaired mTORC1/Rheb interaction (Fig-
ures 5A, S5G, and S5H). Importantly, we also measured the
GTP/GDP-charged state of ectopically expressed GST-Rheb-
wt and endogenous Rheb (Nobukuni et al., 2005; Roccio et al.,
2006; Smith et al., 2005; Wolthuis et al., 1997) with GST pull-
down and immunoprecipitation assays following 32P-labeling
of MCRS1-depleted HEK293T cells in the presence or absence
of AAs. In both endogenous Rheb immunoprecipitation and
GST-Rheb pull-down assays, the GTP/GDP ratio was decreased
when MCRS1 was knocked down, while presence of AAs
increased the ratio by 20% (Figures 5B, 5C, S5I, and S5J).
MCRS1 depletion in TSC2/ MEFs, in which Rheb is not
exposed to TSC1-TSC2 GAP activity, caused no significant dif-
ferences in Rheb-GTP levels (Figures 5D and S5K). Furthermore,
GST-Rheb pull-downs in HCT-116 cells and TSC2-immunoblot-
ting showed that AA or MCRS1 depletion significantly enhanced
Rheb/TSC2 interaction (Figures 5E, S5L, and S5M). Finally, AA-
mediated decreased Rheb/TSC2 interaction was reversed by
MCRS1 depletion (Figure 5F). Thus, MCRS1 and AAs reduce
TSC1-TSC2 binding to Rheb.
Next, we tested whether MCRS1 binds competitively to Rheb,
and, thus, whether MCRS1 and AA depletion increases TSC1-
TSC2 GAP activity toward Rheb. For this, we measured Rheb72 Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc.GTP hydrolysis by incubating bacterially expressed [a-32P] GTP-
labeled GST-Rheb with TSC2 immunoprecipitated from AA-
depleted HEK293T cells and with increased MCRS1 concentra-
tions.Adding increasingamounts ofMCRS1significantly reduced
Rheb-GTP hydrolysis by TSC1-TSC2 GAP activity (Figures 5G
and 5H), indicating increased Rheb/MCRS1 and decreased
Rheb/TSC2 interactions (Figure 5I). However, addition of the Nt
orCt segmentofMCRS1alonewasnot sufficient toconferprotec-
tion from TSC2 GAP activity (Figure 5G). These data indicate that
while Ct segment of MCRS1 was sufficient to bind Rheb, full-
length MCRS1 is required to protect Rheb from TSC2 GAP activ-
ity, suggesting that MCRS1 may not exert its protective role by
competing with TSC2 for Rheb binding but rather by preventing
TSC2/Rheb interaction. Absence of MCRS1 or AAs significantly
increased Rheb GTP hydrolysis by TSC1-TSC2 GAP (Figures 5J
and 5K). Similarly, when GST-Rheb was charged and labeled
with [g-32P]-GTP,MCRS1andAAdepletion increasedGTPhydro-
lysis (Figures 5L–5N). Thus, TSC2 complexes immunoprecipi-
tated following AA or MCRS1 depletion have increased GAP
activity toward Rheb, indicating that AAs and MCRS1 promote
active Rheb scaffolding and hinder TSC1-TSC2 GAP activity.
Furthermore, AA requirement was partially bypassed in Rheb-
overexpressing HeLa cells, but not HEK293T and SW-620 cells
transiently transfected with GST-Rheb (Figure S5N). This
‘‘bypass’’ of AA effects in Rheb-overexpressing cells apparently
depends on mTORC1 downstream targets. For instance, in
HeLa cells 4EBP1 phosphorylation at Ser-65 was sensitive to
AA withdrawal, even with Rheb overexpression, but not phos-
phorylation of S6K1 at Thr-389 and S6 at Ser-240/244 (Fig-
ure S5N). Impaired mTORC1 activity upon AA withdrawal was
also observed following MCRS1 overexpression in all cell types,
indicating that AAs are essential for Rheb andMCRS1 to activate
mTORC1. Notably, overexpressed Rheb colocalized with mTOR
inHEK293T and human osteosarcomaU2-OS cells (Figure S5O).
Thus,MCRS1 is apparently required for AA-dependent mTORC1
activation.
Finally, we assayed mTORC1 kinase activity, which is directly
stimulated by Rheb-GTP (Long et al., 2005a), in vitro in the pres-
ence of recombinant 4EBP1 and immunoprecipitated Raptor
from HEK293T cells transfected with siRNA-Ctr or siRNA-
MCRS1 (Figures 5O and 5P). Thus, MCRS1 and AA depletion
reduced 4EBP1 phosphorylation at Ser-65, establishing a critical
role for MCRS1 in mTORC1 activation.
MCRS1 Maintains Rheb at Lysosomes
in an AA-Dependent Manner
Next, we verified that MCRS1 is a lysosomal membrane-bound
protein, by immunoblotting Rheb, MCRS1, andmTORC1 in frac-
tions separated by a sucrose-density gradient (Figures S6A and
S6B). Furthermore, their lysosomal localization appeared to be
AA dependent, although some mTOR remained lysosomal
following AA deprivation (Figure 6A). Immunofluorescence anal-
ysis confirmed this, showing that15%of cells retained residual
mTOR and Lamp2 colocalization (a lysosomal marker) after AA
depletion (Figure S6C). MCRS1 localization to the lysosomes
was confirmed by immunofluorescence (Figure S6D). Interest-
ingly, MCRS1 FL (1–462) and MCRS1 Ct (256–462) fragment
localized to the lysosomes in presence of AAs but not the domi-
nant-negative part MCRS1 Nt (1–260) (mainly nuclear), consis-
tent with our results shown in Figure S3V.
AAs strengthened MCRS1/Rheb and MCRS1/mTOR interac-
tions, suggesting that mTORC1 AA-sensing machinery might
target MCRS1 to lysosomes. To test this hypothesis, compo-
nents of the v-ATPase (ATP6V0C) and Ragulator complexes
(LAMTOR1) were knocked down in HCT-116 cells. Cells were
also treated with FTI-277 to delocalize lysosomal Rheb.
MCRS1 lysosomal localization was reduced by depleting the v-
ATPase/Ragulator-AAs sensingmachinery and further abolished
by FTI-277 addition (Figures 6B, 6C, S6E, and S6F), indicating
that AAs via v-ATPase/Ragulator machinery may play a role in
MCRS1 recruitment at lysosomal surfaces. Interestingly, overex-
pression of the dominant active mutant RagB (Q99L) (RagBGTP)
constitutively targeted mTORC1 and MCRS1 to lysosomes
where Rheb was retained despites AA depletion (Figures S6G–
S6J). In MCRS1-depleted and RagB (Q99L)-overexpressing
HCT-116 cells, AA-dependent mTORC1 activation was dramat-
ically reduced (Figure 6D). Taken together, these data suggest
that MCRS1, possibly through its binding to mTOR, is partly tar-
geted to the lysosomes through the AA-sensing v-ATPase
machinery.
Accordingly, MCRS1 suppression abolished Rheb detection
in lysosomal fractions, without affecting mTORC1 levels (Figures6E and S6K), independently of its reported interaction with Nde1
and nuclear function, because Nde1 depletion did not affect
Rheb lysosomal localization (Figure S6L). Notably, no Rheb
was detected in lysosomal fractions of TSC2/ cells following
MCRS1 suppression (Figures 6F and S6M), in accordance with
mTOR inhibition and Rheb colocalization and binding by AA
depletion (Long et al., 2005b). Overexpression of a Rheb
construct that was constitutively targeted to the lysosomes
(LAMTOR1-HA-Rheb) maintained mTOR activation upon AA
depletion (Figures 6G–6I). However, this effect was lost upon
MCRS1 depletion, confirming the role of MCRS1 to bridge
mTOR/Rheb interaction (Figure 6G). Finally, overexpression of
MCRS1 construct constitutively targeted to the lysosomes
(LAMTOR1-HA-MCRS1) prevented mTOR inhibition following
AA depletion (Figures 6H and 6J). Thus, MCRS1 is essential for
maintaining Rheb on lysosomes and, couples Rheb to mTORC1
activation in AA responses.
Endogenous mTOR localization to lysosomes following AA
stimulation was unaffected by MCRS1 depletion, as shown by
its colocalization with the lysosomal marker Lamp2 (Figure 6K).
Using a validated antibody in immunofluorescence and recog-
nizing endogenous Rheb on the lysosomes (Figure S6N), we
demonstrated that endogenous Rheb delocalized from lyso-
somes upon AA withdrawal and MCRS1 suppression in HCT-
116 (Figures 6L and 6M) and U2-OS (Figures S6O and S6P) cells,
apparently to another membrane-bound vesicle-like structure,
indicated by its reduced co-staining with lysotracker. Similar re-
sults were obtained upon Rheb overexpression (Figures S6Q–
S6S). Notably, RagC colocalized with Lamp2, indicating that
RagC is lysosomal (Figures S6T and S6U). These results suggest
that MCRS1 maintains Rheb at the lysosmal surfaces in an AA-
dependent manner.
AAs and MCRS1 Protect Rheb from Endosomal
Recycling
The lack of effects of MCRS1 depletion on Rheb farnesylation
suggested that Rheb relocalized to another membrane-bound
compartment, we investigated Rheb localization during the en-
docytic cycle. Endogenous Rheb colocalization with Rab5A, an
early endosomemarker, was not detected in HCT-116 cells (Fig-
ures 7A–7D). However, endogenous Rheb partially colocalized
with Rab7A, a late endosome and lysosome marker (Figures
7E–7H), and AA or MCRS1 depletion reduced Rheb/Rab7A co-
localization (Figures 7E–7I). Furthermore, 10% of endogenous
Rheb colocalized with Rab11A, a marker of recycling endo-
somes, following AA or MCRS1 depletion in HCT-116 (Figures
7J–7N). Overexpressed HA or GST-tagged Rheb following AA
or MCRS1 depletion showed similar patterns to endogenous
Rheb in HCT-116 cells (Figures S7A–S7D) and, similar results
were obtained in HEK293T and U2-OS (Figures S7E–S7M) cells.
Notably, siRNA-mediated Nde1 depletion had no effect on Rheb
localization (Figure S7N). In addition, in TSC2-depleted cells,
Rheb did not colocalize with Rab5A (Figures S7O and S7P),
but colocalized with Rab7A in the presence of AAs and
MCRS1 (Figures S7Q and S7R) and partially shuttled on recy-
cling endosomes, following AA and MCRS1 depletion (Figures
S7S and S7T). Finally, AA depletion, MCRS1, or mTOR knock-
down significantly decreased Rab5A and Rab11A but increased
Rab7A vesicles number in HCT-116 cells (Figure S7U),Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc. 73
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suggesting a role of MCRS1 in the endocytic cycle that may also
depend on mTORC1 activity. We also observed that Rab5A,
Rab7A, and Rab11A vesicle size increased upon AA stimulation
and decreased upon MCRS1 and mTOR knockdown (Fig-
ure S7V), suggesting that increased lysosomal platform is
required for fully operative mTORC1/Rheb/MCRS1 complexes.
TSC2 Is Lysosomal and Does Not Shuttle in Response
to AAs
Interestingly, regardless of the presence of AAs and MCRS1,
TSC2 colocalized with Lamp2 and Rab7A, but not Rab5A or
Rab11A (Figures 8A–8D), indicating that TSC2 resides on lyso-
somes and does not circulate during endocytic cycles in AA re-
sponses. While lysosomal TSC2 localization in response to AAs
was recently debated (Demetriades et al., 2014; Menon et al.,
2014), serum starvation followed by IGF1 addition spatially delo-
calized TSC2 from lysosomes, as previously reported (Menon
et al., 2014) (Figure S8). These results indicate that AA stimula-
tion recruits mTORC1 with MCRS1 to late endosomes/lyso-
somes. MCRS1 maintains Rheb on lysosome surfaces and
protects it from lysosomal TSC1-TSC2 GAP activity, connecting
Rheb/mTORC1. The absence of MCRS1 or AAs favors TSC2/
Rheb interaction and inactivated Rheb, but not TSC2, delocal-Figure 5. MCRS1 Regulates Rheb Activity
(A) HCT-116 cells transfectedwith siRNA-Ctr (control) or siRNA-MCRS1were seru
and then re-stimulatedwith AAs for 10min. Cell lysateswere processed for Rheb-G
antibody.
(B) HEK293T cells were either not transfected or transfected with siRNA-Ctr (con
Cells were then cultured in phosphate-free media for 3.5 hr supplemented with 32
radionuclide and then re-stimulated for 10 min with 10% dialyzed fetal calf serum
Rheb was immunoprecipitated with Rheb C-19 antibody and radioactive GTP/G
(C) Quantification of (B). The ratio of GTP to GDP was detected by Phos
32PGTP/32PGTP + 1.5 3 32PGDP.
(D) TSC2/ MEFs stably expressing sh1RNA against MCRS1 were cultured in th
subjected to Rheb-GTP immunoprecipitation assay.
(E) HCT-116 cells transiently transfected with GST Rheb and treated as in (A). C
(F) GST pull-downs in HCT-116 cells transiently expressing GST-Rheb and transfe
followed by AAs for 1 hr or starved and then re-stimulated by AAs for 10 min.
(G) HEK293T cells were serum-starved for 16 hr followed by AA deprivation for 1
subjected for TSC2 immunoprecipitationandassayed forGAPactivity toward [a-32
amount of GST-MCRS1 (full-length [FL]), Nt-MCRS1 (1–260) or Ct-MCRS1 (256–
(H) Quantification of (G) following the formula %32PGTP=32PGTP/32PGTP
phorImager and the ratio of GTP to GDP was quantified by ImageJ.
(I) HEK293T cells transfected with either GST or GST-Rheb were treated as in (
translated HA-MCRS1.
(J) HEK293T cells were either transfected or not with siRNA-Ctr (control) (lane
deprivation for 1 hr or AA deprivation and then re-stimulated by AAs for 10 min.
toward [a-32P] GTP-loaded bacterial GST-Rheb. Radioactive GTP andGDPwere
using PhosphorImager and the ratio of GTP to GDP was quantified by ImageJ.
(K) Quantification of (J).
(L) TSC2was immunoprecipitated fromHEK293T cells, which were serum-starved
by AAs for 10 min, as indicated. Immunoprecipitates were assayed for GAP activ
Procedures). [g-32P] GTP was eluted from Rheb after a 60 min incubation with th
(M) Quantification of (L) using ImageJ. Data were normalized to IgG.
(N) Scintillation counts of [g-32P] GTP released after hydrolysis.
(O) HEK293T cells were transfected with either siRNA-Ctr (control) (lanes 2 and 3
dialyzed 10%FCSand then re-stimulated for 10minwith dialyzed 10%FCSeither
FCS for 24 hr (lanes 10 and 11) or FCS starved and stimulated with IGF1 for 10
immunoprecipitation using Raptor antibody. Immunoprecipitates were subjecte
Samples were processed for immunoblotting with the indicated antibodies.
(P) Cell lysates used for immunoprecipitation and kinase assays shown in (O).
Statistical analysis was performed using one-way ANOVA test followed by the Ben
and ***p% 0.001.izes from the lysosomes leading to mTORC1 inactivation
(Figure 8E).
DISCUSSION
Full mTORC1 activation requires AAs for its translocation to lyso-
somes, and growth factors that inhibit TSC1-TSC2 GAP activity
toward Rheb (Menon et al., 2014). Loss of TSC1 or TSC2 renders
Rheb hyperactive, constitutively activating mTORC1, which be-
comes resistant to growth factor (but not AA) deprivation (Kim
et al., 2008; Roccio et al., 2006; Sancak et al., 2008; Smith
et al., 2005; Zhang et al., 2003a, 2003b), indicating that AAs
may be essential to convert Rheb to its active (mTOR kinase ac-
tivity-stimulating) GTP-bound form. Rheb-GTP binds to the
mTOR catalytic domain’s amino-terminal lobe and activates
mTOR kinase GTP-dependently (Sato et al., 2009). AA depletion
reduces proportions of active GTP-bound Rheb (Roccio et al.,
2006; Smith et al., 2005), and reversibly inhibits Rheb/mTOR
binding (Long et al., 2005b).
Rheb overexpression can override effects of AA starvation
on mTORC1 inhibition (Garami et al., 2003; Im et al., 2002; In-
oki et al., 2003; Long et al., 2005a, 2005b; Saucedo et al.,
2003; Smith et al., 2005; Stocker et al., 2003; Tee et al.,m-starved for 16 hr followed by AA deprivation for 1 hr or AA deprivation for 1 hr
TP immunoprecipitation using a configuration-specific Rheb-GTPmonoclonal
trol) or siRNA-MCRS1 and grown overnight in 1.5% serum (lanes 1, 2, and 3).
p radionuclide. Cells were AA deprived for 1 hr in HBSS supplemented with 32P
(FCS) either in the absence (lane 4) or presence (lane 5) of AAs. Endogenous
DP eluted nucleotides were resolved with TLC.
phorImager and quantified by ImageJ following the formula %32PGTP=
e absence or presence of IPTG for 36 hr to deplete MCRS1. Cell lysates were
ell lysates were subjected to GST pull-downs.
cted with either siRNA-Ctr or siRNAMCRS1. Cells were serum-starved for 16 hr
hr or starved and then re-stimulated by AAs for 10 min. Cells were lysed and
P]GTP-loadedbacterialGST-Rheb in theabsenceor thepresenceof increasing
462). Radioactive GTP and GDP were resolved with one-dimensional TLC.
+ 1.5 3 32PGDP. Radioactive GTP and GDP were detected by using Phos-
F). GST pull-downs were performed with increased concentrations of in vitro
2) or siRNA-MCRS1 (lane 3) or were serum-starved for 16 hr followed by AA
TSC2 was immunoprecipitated from cell lysates and assayed for GAP activity
resolved by one-dimensional TLC. Radioactive GTP andGDPwere detected by
for 16 hr followed by AA deprivation for 1 hr or deprived and then re-stimulated
ity toward purified bacterial [g-32P] GTP-loaded GST-Rheb (see Experimental
e specified immune complexes and resolved by one-dimensional TLC.
) or siRNA-MCRS1 (lanes 4 and 5) or, were AA-deprived for 1 hr in presence of
in the absence (lanes 6 and 7) or presence (lanes 8 and 9) of AAs or starved from
min (lanes 12 and 13) as indicated. Whole-cell extracts were processsed for
d to in vitro kinase assay using recombinant 4EBP1 protein as a substrate.
ferroni method (C, H, K,M, and N). Errors bars represent ± SD (n = 3). *p% 0.05
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2003). Notably, Rheb overexpression or forced localization of
mTORC1 to lysosomal surfaces (by fusing a lysosomal locali-
zation signal to Raptor) bypasses requirements for Rag-medi-
ated recruitment of mTORC1 and allows mTORC1 activation
in the absence of AAs (Zoncu et al., 2011a). Our results indi-
cate that mTORC1 responses to AA withdrawal are weak
even with Rheb overexpression, which may ectopically stabi-
lize Rheb/mTORC1 complexes, thereby overriding MCRS1
requirement. However, these complexes are only partially acti-
vated upon AA depletion, depending on cell type and down-
stream targets modulated by mTORC1 stimulation. AAs may
putatively activate mTORC1 Rheb-independently via confor-
mational changes in mTOR/Raptor complexes that impair their
ability to phosphorylate substrates (Hay and Sonenberg, 2004),
but our findings indicate that AAs target MCRS1 to lysosomes,
maintaining and connecting active Rheb to mTORC1
activation.
It is currently uncertain which specific AAs are sensed to acti-
vate mTORC1, although leucine, L-glutamine, and arginine have
been implicated in mTORC1 activation (Jewell et al., 2015; Re-
bsamen et al., 2015; Wang et al., 2015). The AA-sensing
v-ATPase lysosomal machinery is necessary to target mTOR to
the lysosomes. This samemachinery is partly required to localize
MCRS1 to the lysosomes, possibly through its binding to mTOR.
Additionally, leucine and non-essential AAs containing L-gluta-
mine and arginine are necessary in maintaining MCRS1/Rheb
interaction, independently of v-ATPase and Ragulator, suggest-
ing that different AA-sensing pathways channel to MCRS1.
Recent studies reportedly described that the cytoplasmic
leucyl-tRNA synthetase (LeuRS) acts as a direct sensor of
leucine and is implicated in mTORC1 activation (Bonfils et al.,
2012; Han et al., 2012), and mTORC1 is differentially regulated
by glutamine and leucine through distinct mechanisms that
require Arf1 or Rag GTPases, respectively (Jewell et al., 2015).
Further work is needed to better understand how different AAs
signal to MCRS1 and to regulate mTORC1 activity.Figure 6. MCRS1 Maintains Rheb at Lysosomes in an AA-Dependent M
(A) Immunoblots of lysosomal fractions of HCT-116 cells that were serum-starved
re-stimulated with AAs for 10 min.
(B) HCT-116 cells were transfected either with siRNA-Ctr, siRNA-ATP6V0C, or
stimulation, cells were treated as in (A) and were subjected to lysosomal fraction
(C) Cell lysates of (B) used for loading control.
(D) HCT-116 cells were transiently transfected with either an empty plasmid o
stimulation, cells were treated as in (A).
(E) Lysosomal fractions of HCT-116 cells cultured under normal conditions and tr
Life Technologies (LT), or Santa Cruz (SC).
(F) Lysosomal fractions of TSC2/ MEFs stably expressing sh1RNA against MC
(G) HCT-116 cells were transfected with either siRNA-Control or siRNA-MCRS1 a
treated as in (A).
(H) HCT-116 cells transiently expressing either HA empty vector, LAMTOR1-HA-R
(I) Immunofluorescence images of staining for Lamp2 (green), mTOR (green) and
stimulation, cells were treated as in (A).
(J) Immunofluorescence images of staining for Lamp2 (green), mTOR (green), and
stimulation, cells were treated as in (A).
(K and L) Staining for Lamp2/mTOR (K) or endogenous Rheb/Lysotracker (L) in H
stimulation, cells were treated as in (A). DNA was labeled with 40,60-diamidino-2-
that overlay.
(M) Quantification of Rheb’s colocalization with lysotracker from (L).
Statistical analysis was performed using one-way ANOVA test followed by the B
***p% 0.001.
Scale bars represent 5 mm.Nutrient regulation of mTORC1 signaling is functionally
conserved across eukaryotes. Database searches detected no
potential MCRS1 orthologs in yeasts, despite high MCRS1 con-
servation among multicellular eukaryotes. Furthermore, TSC1,
TSC2 (Hay and Sonenberg, 2004; Long et al., 2002), and Ragu-
lator (Sancak et al., 2010) are not conserved in Saccharomyces
cerevisiae. Although a Rheb homolog has been identified in
S. cerevisiae, phylogenetic analyses indicate that the Rheb or-
tholog in budding yeast does not appear to regulate TOR
pathway (Aspuria and Tamanoi, 2004; Berchtold and Walther,
2009). Notably, even following AA depletion, TOR appears to
remain bound to vacuoles (lysosome counterparts) in S. cerevi-
siae. In contrast to budding yeast, conservation of the TSC/
Rheb/TOR signaling pathway in fission yeast (Schizosaccharo-
myces pombe) andmammalian cells (Aspuria et al., 2007) argues
that MCRS1 evolved in multicellular organisms later after TSC
and Rheb proteins, acquiring an mTORC1-activation regulatory
role.
Interestingly, mice lacking components described to be crit-
ical in mTORC1 activation, such as Rheb (Goorden et al.,
2011), Ragulator (Nada et al., 2009; Teis et al., 2006), Raptor
(Guertin et al., 2006), or mTOR itself (Gangloff et al., 2004),
die at early days of embryonic development (between 6 and
8 days). Although further analysis is required, the complete
knockout of MCRS1 also results in embryonic lethality (not
shown). Because MCRS1 is essential for mTORC1 function,
which is necessary to support normal development in em-
bryos, we would therefore not be surprised that mice lacking
MCRS1 may die at an earlier time than other mTORC1
components.
MCRS1 was initially described as a nucleolar protein p120 in-
teractor (Ren et al., 1998), associated with transcription regula-
tion (Andersen et al., 2010; Ivanova et al., 2005; Lin and Shih,
2002; Wu et al., 2009). However, it participates in other
processes, including cellular senescence (Hsu et al., 2012), cell
division, and survival by interacting with the centrosomal proteinanner
for 16 hr followed by AA deprivation for 1 hr or AA deprivation for 1 hr and then
siRNA-LAMTOR1 or treated with FTI-277 farnesyl inhibitor or both. For AA
ation.
r RagB (Q99L) and with either siRNA-Ctr (control) or siRNA-MCRS1. For AA
eated with either siRNA-Ctr (control) or siRNA-MCRS1 from Dharmacon (DM),
RS1 cultured for 36 hr in the presence of IPTG to deplete MCRS1.
nd transiently expressing LAMTOR1-HA-Rheb. For AA stimulation, cells were
heb or LAMTOR1-HA-MCRS1. For AA stimulation, cells were treated as in (A).
HA (red) in HCT-116 cells transiently expressing LAMTOR1-HA-Rheb. For AA
HA (red) in HCT-116 cells transiently expressing LAMTOR1-HA-MCRS1. For AA
CT-116 cells transfected either with siRNA-Ctr or with siRNA-MCRS1. For AA
phenylindole (DAPI) (blue). In all images, insets show selected magnified fields
enferroni method (M). Errors bars represent ± SD (n = minimum of ten cells).
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Figure 7. AAs and MCRS1 Protect Rheb
from Its Endosomal Recycling
(A–D) HCT-116 cells transiently expressing GFP-
Rab5A and transfected with siRNA-Ctr (control) or
siRNA-MCRS1 were serum-starved for 16 hr fol-
lowed by 1 hr AA deprivation or by 1 hr AA depri-
vation and subsequently re-stimulated by addition
of AAs for 10 min. Endogenous Rheb is detected
using a specific antibody. Representative im-
munofluoresence images are shown. Inset shows
a higher magnification of a selected field.
(E–I) HCT-116 cells transiently expressing GFP-
Rab7A were treated as in (A)–(D). Endogenous
Rheb is detected using a specific antibody.
Immunofluorescence images are shown (E–H) as
well as quantification of the pixel colocalization
using ImageJ (I).
(J–N) HCT-116 cells transiently expressing GFP-
Rab11A were treated as in (A)–(D). Endogenous
Rheb is detected using a specific antibody.
Immunofluorescence images are shown (J–M) as
well as quantification of the pixel colocalization
using ImageJ (N).
Statistical analysis was performed using one-way
ANOVA test followed by the Benferroni method (I
and N). Errors bars represent ± SD (n = 3). **p %
0.01 and ***p% 0.001.
Scale bars represent 5 mm.Nde1 (Hirohashi et al., 2006) and is reportedly an essential
RanGTP-regulated factor for bipolar spindle assembly protect-
ing them from depolymerization (Meunier and Vernos,
2011MCRS1 regulates mTORC1 independently of microtubule
networks and its nuclear function argues that cells may contain
several MCRS1 pools with different functions, without excluding
a general role of MCRS1 in scaffolding small GTPase proteins.
The potential of farnesyltransferase inhibitors to treat cancer
by impairingmembrane-bound small GTPases functions is being
tested (Berndt et al., 2011). However, inhibiting MCRS1 might
offer an attractive and innovative option for treating various pa-
thologies, including diabetes mellitus and cancer.
EXPERIMENTAL PROCEDURES
Materials, Antibodies, siRNA, shRNAs, Plasmids, Cell Culture,
Transfections, Cell Number, and Size
All details are provided in the Supplemental Experimental Procedures.
Immunoblotting, Immunoprecipitation, and GST Pull-Down Assays
All assays were performed as previously described (Djouder et al., 2007, 2010)
and detailed in the Supplemental Experimental Procedures.
In Vitro Protein Binding Assays
Assays were performed as detailed in the Supplemental Experimental
Procedures.78 Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc.In Vitro Kinase Assays
Detailed protocol is provided in the Supplemental
Experimental Procedures.
Measurement of Rheb Nucleotide State
The activated/active state of Rheb, i.e., the
percent of Rheb molecules in the active GTP
bound state, was determined for the endogenousprotein using the Rheb Activation Assay Kit utilizing a configuration-specific
monoclonal antibody that recognizes and immunoprecipitates Rheb-GTP
but not Rheb-GDP. The measurement of GTP/GDP charged state of Rheb
was assayed as described earlier (Nobukuni et al., 2005; Roccio et al., 2006;
Smith et al., 2005; Wolthuis et al., 1997). Detection was performed using a
PhosphorImager and quantification using ImageJ. Assays were performed
as detailed in the Supplemental Experimental Procedures.
Measurement of TSC2 GAP Activity
TSC2 GAP-stimulated Rheb GTP hydrolysis was measured as described pre-
viously (Li et al., 2006). Briefly, GST-Rheb GTP loaded was incubated with
TSC2 immunoprecipitates in GAP assay buffer (20 mM Tris-HCl pH 8,
10 mM MgCl2, and 1 mM DTT) for 60 min at room temperature. GTP and
GDP nucleotide were eluted, and resolved with thin layer chromatography
(TLC) on PEI cellulose with KH2PO4 as the solvent. Specific details are pro-
vided in the Supplemental Experimental Procedures.
Immunofluorescence
Immunofluorescence assays were performed as detailed in the Supplemental
Experimental Procedures.
Histopathology and Immunohistochemistry
Histopathology and immunohistochemistry were performed as detailed in the
Supplemental Experimental Procedures.
Subcellular Fractionation
Nuclear, cytoplasmic, mitochondrial, and lysosomal fractionations were per-
formed as described in the Supplemental Experimental Procedures. To obtain
the lysosomal fraction, the supernatant from the mitochondrial fractionation
Figure 8. TSC2 Is Lysosomal and Does Not Shuttle in Response to AAs
(A) Immunofluorescence images of endogenous Lamp2 (green) and TSC2 (red) in HCT-116. Cells were either transfected with siRNA-Ctr (control) or siRNA-
MCRS1were serum-starved for 16 hr followed by 1 hr AA deprivation or by 1 hr AA deprivation and subsequently re-stimulated by addition of AAs for 10min. Cells
were then fixed with 4% PFA and then treated with 0.05% dodecyltrimethylammonium chloride for 15 min prior to blocking and labeling with primary and
secondary antibodies.
(B–D) Immunofluorescence images of endogenous TSC2 in HCT-116 cells transiently expressing GFP-Rab5A (green) (B), GFP-Rab7A (green) (C), or GFP-
Rab11A (green) (D) and treated as in (A).
(E) Model for the role of MCRS1 in AA-dependent TORC1 activation.
Scale bars represent 5 mm.was recovered and submitted to the lysosomal extraction using the lysosomal
isolation kit following the manufacturer’s instructions. Protein concentrations
of the fractions were determined (DC Protein Assay, Bio-Rad Laboratories)
and equal amounts of each fraction were subjected for SDS-PAGE and west-
ern blotting with the indicated proteins.
Mass Spectrometry Analysis
GST pull-downs from cells transiently expressing GST or GST-Rheb were per-
formed. Protein digestion was accomplished in solution or in gel, and desalted
peptides were separated by reverse phase chromatography using a nanoLC
Ultra 1D+ system (Eksigent) and directly coupled with a LTQ-Orbitrap Velos
instrument (Thermo Fisher Scientific) via nanoelectrospray source (Proxeon-
Biosystem). Data analysis of raw files was done using the ProteomeDiscoverer
1.3.0.339 software suite (Thermo Scientific). Specific details are provided in
the Supplemental Experimental Procedures.
Size Exclusion Chromatography
Size exclusion chromatography was performed as detailed in the Supple-
mental Experimental Procedures.
Generation and Handling of MCRS1 Conditional Knockout Mouse
Generation of MCRS1 conditional knockout (cKO) was achieved as detailed in
the Supplemental Experimental Procedures. All experiments were approvedby the CNIO-ISCIII Ethics Committee and performed in accordance with the
guidelines for ethical conduct in the care and use of animals as stated in the
international guiding principles for biomedical research involving animals,
developed by the Council for International Organizations of Medical Sciences.
Human Samples
Human samples were obtained from the CNIO-Biobank. The construction and
analysis of a tissue microarray of colon cancer was approved by the appro-
priate ethics committee and informed consent was obtained from all subjects.
Statistical Analyses
Statistical analyseswere performed usingGraphPad Prism V5.0 software. Sta-
tistical significance was considered at *p% 0.05, **p% 0.01, and ***p% 0.001
between the means of a minimum of three groups was determined using un-
paired two-tailed Student’s t test or one-way ANOVA or two-way ANOVA test
as indicated in the figure legends. Results are expressed as the mean value ±
SD. Immunoblots are representative of at least three independent experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at http://dx.doi.
org/10.1016/j.devcel.2015.02.010.Developmental Cell 33, 67–81, April 6, 2015 ª2015 Elsevier Inc. 79
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